Background
Previous studies conducted on the association between diabetes and the risk of endometrial cancer have reported controversial results that have raised a variety of questions about the association between diabetes and the incidence of this cancer. Thus, the aim of this systematic review and meta-analysis was to more precisely estimate the effect of diabetes on the risk of endometrial cancer incidence.
Methods
All original articles were searched in international databases, including Medline (PubMed), Web of sciences, Scopus, EMBASE, and CINHAL. Search was done from January 1990 to January 2018 without language limitations. Also, logarithm and standard error logarithm relative risk (RR) were used for meta-analysis.
Results
A total of 22 cohort and case-control studies were included in this meta-analysis, of which 14 showed statistically significant associations between diabetes and risk of endometrial cancer. Diabetes was associated with increased risk of endometrial cancer (RR = 1.72, 95% CI 1.48–2.01). The summary of RR for all 9 cohort studies was 1.56 (95% CI 1.21–2.01), and it was 1.85 (95% CI 1.53–2.23) for 13 case control studies. The summary of RR in hospital-based studies was higher than other studies. Thirteen of the primary studies-controlled BMI as a confounding variable, and the combined risk of their results was 1.62 (95% CI 1.34–1.97).
Conclusions
Diabetes seems to increases the risk of endometrial cancer in women, and this finding can be useful in developing endometrial cancer prevention plans for women having diabetes.
According to 2012 estimates of cancer, leukemia is the most common childhood malignancy worldwide, followed by brain and nervous malignancies, Non-Hodgkin lymphoma (NHL), renal tumors, and Hodgkin's lymphoma (HL) (Park et al., 2016). Leukemia is caused by abnormal changes in bone
Objective:
Pancreatic cancer is one of the leading causes of mortality in developed countries and a lethal
malignant neoplasm worldwide. This study aims to evaluate the epidemiology of pancreatic cancer
incidence and mortality and its relationship with HDI.
Methods:
This is a descriptive cross-sectional study that is based on cancer incidence data and cancer
mortality rates derived from the World Bank for Cancer in 2018.
The incidence and mortality rates of Pancreas as well as Pancreas cancer distribution maps were derived for
world countries. The data analysis was conducted using correlation test, and regression tests were used to
evaluate the correlation of the incidence and mortality of Pancreas with HDI. The statistical analysis was
carried out by Stata-14, and a significance level of 0.05 was considered.
Results:
The highest incidence of pancreatic cancer was reported in Asia with 214499 (46.7%) cases and the
lowest incidence was related to Oceania with 4529 cases (99.9%). The results showed a positive and
significant correlation between incidence (R = 0.764, P <0.0001) and mortality (R = 0.0.771, P <0.0001) of
pancreatic cancer and the HDI index. The results of ANOVA revealed that the highest mean incidence was
related to the very high HDI (P <0.0001) and the highest mortality was connected to the very high human
development (P <0.0001). The results exhibited that incidence was positively and significantly correlated
with GNI (r = 0.497, P <0.0001), MYS (r = 0.746, P <0.0001), LEB (r = 0.676, <0.0001) and EYS (r =
0.738, P <0.0001). Also, a significant positive correlation was found between mortality and GNI (r = 0.507,
P <0.0001), MYS (r = 0.745, P <0.0001), LEB (r = 0.679, <0.0001), and EYS (r = 0.748, P <0.0001).
Conclusion:
Given the higher incidence and mortality of pancreatic cancer in countries with HDI, it is necessary to pay a
greater attention to risk factors and appropriate planning to reduce these factors and minimize the impact and
mortality rate of this disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.